Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 2/20 | 0.56 |
| ▸ | TPMT | P51580 | 1/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.41 |
| ▸ | HCAR1 | Q9BXC0 | 1/20 | 0.41 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.41 |
| ▸ | TSHR | P16473 | 2/20 | 0.40 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.40 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.40 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.40 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.40 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.39 |
| ▸ | HTR3B | O95264 | 1/20 | 0.39 |
| ▸ | HTR3A | P46098 | 1/20 | 0.39 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.39 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.39 |
| ▸ | RXRA | P19793 | 1/20 | 0.39 |
| ▸ | RXRB | P28702 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL349820 | 0.95 | PARP1 (0.60) | PARP1TPMTCYP3A4SMN1; SMN2ADRA1D | |
| Hydrochloric Acid SCHEMBL4371939 | 0.92 | PARP1 (0.58) | PARP1TPMTCYP3A4SMN1; SMN2ADRA1D | |
| SCHEMBL5048829 | 0.90 | PARP1 (0.60) | PARP1TPMTCYP3A4SMN1; SMN2ADRA1D | |
| SCHEMBL28037673 | 0.82 | PARP1 (0.48) | PARP1TPMTADRA1DHCAR1MAP4K4 | |
| SCHEMBL4339312 | 0.81 | HCAR1 (0.65) | PARP1TPMTCYP3A4SMN1; SMN2ADRA1D | |
| SCHEMBL9631667 | 0.79 | PARP1 (0.50) | PARP1TPMTCYP3A4SMN1; SMN2ADRA1D | |
| SCHEMBL1363329 | 0.79 | PARP1 (0.50) | PARP1TPMTCYP3A4SMN1; SMN2ADRA1D | |
| SCHEMBL22383502 | 0.79 | PARP1 (0.50) | PARP1TPMTADRA1DHCAR1MAP4K4 | |
| SCHEMBL30463182 | 0.79 | PARP1 (0.50) | PARP1TPMTCYP3A4SMN1; SMN2ADRA1D | |
| SCHEMBL16952186 | 0.79 | PARP1 (0.50) | PARP1TPMTCYP3A4SMN1; SMN2ADRA1D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9364466-B2 | Heterocyclic compounds as protein kinase inhibitors | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2016-06-14 | — | — | US | disclosed |
| US-20150157613-A1 | HETEROCYCLIC COMPOUNDS AS PROTEIN KINASE INHIBITORS | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2015-06-11 | — | — | US | disclosed |
| US-8980911-B2 | Heterocyclic compounds as protein kinase inhibitors | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2015-03-17 | — | — | US | disclosed |
| US-20140155398-A1 | HETEROCYCLIC COMPOUNDS AS PROTEIN KINASE INHIBITORS | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2014-06-05 | — | — | US | disclosed |
| WO-2012160464-A1 | HETEROCYCLIC COMPOUNDS AS PROTEIN KINASE INHIBITORS | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2012-11-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150157613-A1 | HETEROCYCLIC COMPOUNDS AS PROTEIN KINASE INHIBITORS | MAP3K1, JAK2, AKT1 | PARP1 2015/4885TPMT 1296/4885CYP3A4 2269/4885 |
| US-20140155398-A1 | HETEROCYCLIC COMPOUNDS AS PROTEIN KINASE INHIBITORS | MAP3K1, JAK2, AKT1 | PARP1 2015/4885TPMT 1296/4885CYP3A4 2269/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.